Ambrilia Biopharma Inc. (TSX: AMB), a biopharmaceutical company developing innovative therapeutics in the fields of cancer and infectious diseases, announced today positive results of a Phase Ia clinical study for PPL-100 its lead protease inhibitor (PI) for the treatment of HIV/AIDS. PPL-100 was found to be safe and well-tolerated. The pharmacokinetic (PK) profile also indicates that PPL-100 can be used as a first-line, un-boosted once-a-day (QD) protease inhibitor for PI-naive patients, and furthermore predicts (based on PPL-100’s phase Ia PK profile, a long half life up to 36 hours and known single dose to steady state PK profile) that PPL-100 can also be used as an un-boosted once-a-day protease inhibitor for PI-experienced patients infected with drug resistant HIV strains containing highly prevalent mutations.
